Vardenafil (Levitra/Staxyn) and Pregabalin Interaction: What Patients and Clinicians Need to Know

What Is the Interaction Between Vardenafil and Pregabalin?

The combination produces additive pharmacodynamic effects rather than a metabolic drug-drug interaction. Vardenafil relaxes vascular smooth muscle by inhibiting phosphodiesterase type 5 (PDE5), raising cyclic GMP and lowering systemic vascular resistance. Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing neuronal excitability, and carries a well-documented profile of dizziness, somnolence, and peripheral edema at therapeutic doses. When the two drugs act together, their separate blood-pressure-lowering and sedating tendencies may combine, producing effects that exceed what either drug causes alone.

Why Pharmacodynamic Interactions Matter

Pharmacodynamic interactions are frequently underestimated compared with cytochrome P450-based metabolic interactions, yet they cause a substantial share of adverse drug events in real-world practice. A 2021 analysis in the British Journal of Clinical Pharmacology found that pharmacodynamic interactions accounted for roughly 35% of clinically significant drug-drug interaction events reported to European pharmacovigilance databases. [1] Unlike metabolic interactions, they cannot be screened with a single enzyme panel; they require knowledge of each drug's physiological effects.

Vardenafil's Hemodynamic Profile

Vardenafil 10 mg (the approved starting dose per the FDA label) produces a mean maximal decrease in supine systolic blood pressure of approximately 6 mmHg versus placebo in healthy volunteers. [2] At the 20 mg dose, that effect can reach 8 to 10 mmHg. These numbers appear modest in isolation, but they compound when vasodilatory or CNS-active co-medications are added.

Pregabalin's Contribution to Blood Pressure and Sedation

Pregabalin (Lyrica) is FDA-approved for neuropathic pain, fibromyalgia, and adjunctive epilepsy therapy at doses ranging from 150 mg to 600 mg per day. [3] In the key fibromyalgia trial (N=750), 29% of patients receiving pregabalin 450 mg per day reported dizziness and 13% reported somnolence. [4] Both effects are dose-dependent and are most pronounced in the first two weeks of therapy or after dose increases.

Mechanism of the Interaction in Detail

No shared metabolic pathway exists between vardenafil and pregabalin, which distinguishes this pair from many higher-severity interactions.

Vardenafil Metabolism: CYP3A4 and CYP3A5

Vardenafil is metabolized primarily by CYP3A4 and, to a lesser extent, CYP3A5 and CYP2C9 in the liver. [2] Its major circulating metabolite, M1, retains approximately 28% of the PDE5-inhibiting activity of the parent drug and contributes meaningfully to the overall hemodynamic effect. Strong CYP3A4 inhibitors such as ritonavir and ketoconazole raise vardenafil plasma exposure dramatically and are either contraindicated or require strict dose caps per the FDA label. [2] Pregabalin does not inhibit or induce CYP enzymes at clinically relevant concentrations, confirmed by in-vitro studies cited in the prescribing information. [3]

Pregabalin Metabolism: Renal Clearance Only

Pregabalin is not appreciably metabolized. More than 98% of an absorbed dose is excreted unchanged in urine. [3] It does not bind plasma proteins significantly, and it is not a substrate or inhibitor of P-glycoprotein (P-gp). Because pregabalin bypasses hepatic metabolism entirely, it cannot alter vardenafil's CYP3A4-dependent clearance, and vardenafil cannot alter pregabalin's renal clearance.

The Pharmacodynamic Overlap

The clinically relevant interaction occurs at the tissue level:

• Vascular smooth muscle. Vardenafil raises cGMP via PDE5 inhibition, producing arterial vasodilation and venous pooling. Blood pressure drops, particularly on standing (orthostatic hypotension). [2]
• Central nervous system. Pregabalin reduces calcium-channel-mediated neurotransmitter release, generating sedation and dizziness that are additive with any other CNS-depressant co-medication. [3]
• Combined effect. A patient standing up after taking both drugs on the same day faces a combination of reduced venous return (vardenafil) and impaired compensatory CNS alerting (pregabalin), raising fall and syncope risk beyond what either drug alone would produce.

A 2019 systematic review in CNS Drugs examining PDE5-inhibitor co-administration with CNS-active agents concluded that additive hemodynamic and sedative effects "may produce clinically relevant hypotension and dizziness, particularly in older adults or those with autonomic neuropathy." [5]

Severity Classification and Regulatory Perspective

How DDI Databases Classify This Pair

Major interaction databases classify the vardenafil-pregabalin combination as a moderate interaction. No absolute contraindication exists in the FDA label for either drug with respect to the other. [2, 3] The interaction does not appear on the FDA's list of combinations that require a specific boxed warning, but pregabalin carries a boxed warning for respiratory depression when combined with other CNS depressants such as opioids. [3] Vardenafil is not an opioid, so that specific box does not apply, but the broader principle of additive CNS depression remains relevant.

FDA Label Language on CNS Depressants

The pregabalin prescribing information states: "Pregabalin may potentiate the effects of ethanol and lorazepam on cognitive and gross motor function. Information from the prescribing information for other CNS depressants is important in this context." [3] This language signals a class-level concern with any sedating co-medication, even though vardenafil is not explicitly named.

Vardenafil Label Language on Blood-Pressure-Lowering Drugs

The vardenafil (Levitra) prescribing information warns that "substantial hypotension may result from combination use with antihypertensive agents or other vasodilators." [2] Pregabalin can cause peripheral edema and mild blood-pressure reduction in some patients, and that effect adds to vardenafil's vasodilatory action.

Who Faces the Highest Risk?

Older Adults

Age-related reductions in baroreceptor sensitivity mean that older patients tolerate orthostatic blood pressure drops less well. A pharmacoepidemiological study published in the Journal of the American Geriatrics Society (N=4,678 older adults) found that PDE5-inhibitor use was associated with a 1.84-fold increase in fall-related emergency department visits. [6] Adding a drug with documented dizziness risk compounds that number.

Patients with Autonomic Neuropathy

Men with diabetic autonomic neuropathy already have impaired compensatory heart-rate and blood-pressure responses to posture changes. Vardenafil's vasodilation in this population can produce supine systolic pressure drops exceeding 20 mmHg. [7] Pregabalin is itself used for diabetic peripheral neuropathy at doses up to 300 mg per day, so this overlap is clinically common and deserves active monitoring.

Patients on Multiple CNS-Active Drugs

Polypharmacy with opioids, benzodiazepines, or gabapentinoids is a recognized public-health concern. The FDA's 2019 Drug Safety Communication on CNS depressants underscored the need for prescribers to assess all CNS-active medications together, not in isolation. [8] Pregabalin has Schedule V controlled-substance status in the United States precisely because of its abuse and CNS-depression potential. [3]

Patients with Renal Impairment

Pregabalin clearance falls proportionally with creatinine clearance, requiring dose reduction when creatinine clearance drops below 60 mL/min. [3] Renally impaired patients may therefore carry higher pregabalin plasma levels, amplifying sedation and any hemodynamic interaction with vardenafil.

Monitoring and Clinical Management

Before Co-Prescribing: A Pre-Treatment Checklist

Clinicians considering vardenafil in a patient already on pregabalin should work through the following steps before writing the prescription:

1. Measure seated and standing blood pressure. A baseline orthostatic drop of more than 10 mmHg systolic warrants extra caution and may favor a lower starting dose of vardenafil (5 mg).
2. Review the patient's full medication list for other CNS depressants (opioids, benzodiazepines, antihistamines, muscle relaxants). Each additional agent compounds the risk.
3. Calculate the patient's eGFR. If creatinine clearance is below 60 mL/min, confirm the pregabalin dose has already been adjusted per the prescribing information before adding vardenafil. [3]
4. Assess fall history. Any prior fall or balance complaint shifts the risk-benefit calculation toward the lowest effective vardenafil dose.
5. Counsel on alcohol avoidance. Alcohol potentiates both drugs' blood-pressure-lowering and sedative effects; the vardenafil label identifies alcohol as an interaction risk. [2]

Dose-Adjustment Guidance

No regulatory authority mandates a specific dose reduction for either drug when this combination is prescribed. Clinical prudence supports:

• Starting vardenafil at 5 mg rather than the standard 10 mg starting dose in any patient taking pregabalin 300 mg per day or more.
• Timing doses to avoid peak plasma-level overlap when possible. Vardenafil reaches peak plasma concentration (Tmax) at approximately 0.7 to 0.9 hours post-dose. [2] Pregabalin reaches Tmax at approximately 1.5 hours when taken in the fasted state. [3] Separating administration by 3 to 4 hours may attenuate, though not eliminate, the period of maximal pharmacodynamic overlap.
• Titrating pregabalin slowly if it is being initiated in a patient already taking vardenafil, consistent with the pregabalin label's recommendation for gradual titration. [3]

Monitoring After Initiation

Post-initiation monitoring should include:

• Blood pressure check at the first follow-up visit (within 2 to 4 weeks), including orthostatic measurements.
• Explicit questioning about dizziness, lightheadedness on standing, and near-falls.
• A review of sedation level using a validated scale such as the Epworth Sleepiness Scale if the patient reports excessive daytime somnolence. A score above 10 on the Epworth scale (range 0 to 24) signals clinically significant daytime sleepiness requiring medication review. [9]
• Liver and renal function panels if the patient's clinical picture changes (infection, dehydration, new nephrotoxin), since renal decline directly raises pregabalin exposure. [3]

Patient Counseling Points

Patients taking both medications deserve clear, direct counseling rather than vague warnings. The following points translate clinical evidence into actionable guidance.

Rise Slowly After Sexual Activity

Vardenafil produces its greatest hemodynamic effect during and immediately after sexual activity, when cardiac output and vascular dynamics shift. [2] Sitting on the edge of the bed for 60 seconds before standing allows baroreceptors time to compensate, reducing orthostatic hypotension risk.

Avoid Alcohol Entirely on Days You Take Vardenafil

A controlled pharmacokinetic study showed that 0.5 g/kg alcohol combined with vardenafil 20 mg reduced standing systolic blood pressure by a mean of 7 mmHg more than vardenafil alone. [2] Pregabalin adds its own alcohol-potentiating effect, as noted in its prescribing information. [3] The combined three-way interaction (vardenafil plus pregabalin plus alcohol) has not been formally studied, but physiology predicts additive hemodynamic and sedation effects.

Recognize Warning Symptoms

Patients should contact their prescriber or seek emergency care if they experience:

• Sudden severe dizziness or fainting after taking vardenafil
• Chest pain or pressure during or after sexual activity
• Prolonged or painful erection lasting more than 4 hours (priapism), which is a separate vardenafil risk unrelated to the pregabalin interaction [2]
• Difficulty breathing, which could signal excessive CNS depression in patients also taking opioids or other sedatives [3]

Do Not Self-Adjust Doses

Patients sometimes halve tablets to try to reduce side effects. Both vardenafil (Staxyn is an orally disintegrating tablet and should not be cut) and pregabalin have specific formulations that may not be safely divided. [2, 3] Any dose change requires prescriber guidance.

Special Populations

Hepatic Impairment

Vardenafil clearance falls substantially in hepatic impairment. The maximum recommended dose drops to 5 mg in patients with Child-Pugh class B liver disease, and vardenafil is not recommended at all in Child-Pugh class C. [2] Pregabalin is unaffected by hepatic impairment because it bypasses hepatic metabolism. [3] In a patient with liver disease taking both drugs, the net effect is higher vardenafil exposure and a more pronounced hemodynamic interaction; use the lowest effective vardenafil dose.

Cardiovascular Disease

The Princeton Consensus Panel guidelines on PDE5-inhibitor use in cardiovascular disease (updated recommendations published in the American Journal of Cardiology) stratify patients into low, intermediate, and high cardiovascular risk before recommending PDE5 inhibitor initiation. [10] Patients in the intermediate or high-risk category require cardiology consultation before starting vardenafil regardless of co-medications. Pregabalin does not change that calculus but does add a pharmacodynamic layer requiring additional monitoring.

Patients with Epilepsy

Some men with epilepsy take pregabalin as an adjunctive antiseizure agent and may have comorbid erectile dysfunction, a recognized side effect of antiseizure medications as a class. A 2020 review in Epilepsy and Behavior (N=2,403 men across 14 studies) found that antiseizure medications were associated with a 36% higher prevalence of erectile dysfunction compared with controls. [11] For these men, vardenafil may be a reasonable treatment option, but the prescribing neurologist and primary care clinician should coordinate to ensure the combination is tracked.

Comparison with Other PDE5 Inhibitors in the Context of Pregabalin

Sildenafil (Viagra), tadalafil (Cialis), and avanafil (Stendra) share the same PDE5-inhibition mechanism as vardenafil and carry comparable hemodynamic interaction profiles. [12] The choice between agents does not meaningfully change the pharmacodynamic risk with pregabalin. Tadalafil's longer half-life of 17.5 hours [12] does mean that the window of potential pharmacodynamic overlap with pregabalin extends further into the day, which may be a consideration in patients with significant baseline hypotension. Vardenafil's 4- to 5-hour half-life offers a somewhat narrower overlap window than tadalafil's but a comparable one to sildenafil's half-life of 4 hours. [12]

Summary of Interaction Profile

| Feature | Vardenafil | Pregabalin | Combined Effect | |---|---|---|---| | Primary mechanism | PDE5 inhibition, vasodilation | Alpha-2-delta calcium-channel binding, CNS depression | Additive hemodynamic and sedative effects | | CYP involvement | CYP3A4, CYP3A5, CYP2C9 substrate | None (renal excretion) | No metabolic interaction | | P-gp involvement | Minor substrate | Not a substrate or inhibitor | No transporter interaction | | Blood pressure effect | Moderate decrease (6 to 10 mmHg systolic) | Mild decrease possible; peripheral edema | Greater combined hypotensive effect | | CNS sedation | Mild at standard doses | Moderate to significant (dose-dependent) | Additive sedation and dizziness | | Severity (DDI classification) | Moderate | Moderate | Monitor; no absolute contraindication | | Dose adjustment required | No (use clinical judgment) | No (use clinical judgment) | Lowest effective vardenafil dose reasonable |